Condition: Gallbladder Neoplasms
Intervention:
Sponsors: Shanghai Jiao Tong University School of Medicine; The First Affiliated Hospital of Anhui Medical University; Anhui Provincial Hospital; First Affiliated Hospital Bengbu Medical College; LanZhou University; Henan Cancer Hospital; The First Affiliated Hospital of Zhengzhou University; The Second Affiliated Hospital of Harbin Medical University; First Affiliated Hospital of Harbin Medical University; Harbin Medical University; First Hospital of Jilin University; Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University; Changshu NO.1 People's Hospital; Changzhou No.2 People's Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China; The First People's Hospital of Taicang; Wuxi Second People's Hospital; Xuzhou Central Hospital; Second Affiliated Hospital of Suzhou University; Nantong University; The First People's Hospital of Nantong; The Affiliated Hospital of Xuzhou Medical University; Second Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University; Jiangxi Provincial People's Hopital; Shengjing Hospital; Baotou Central Hospital; Qinghai Provincial People's Hospital; Heping Hospital Affiliated to Changzhi Medical College; First Hospital of Shanxi Medical University; Shanxi Provincial Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; Eastern Hepatobiliary Surgery Hospital; Shanghai Fengxian District Central Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Zhongshan Hospital; Shanghai Pudong Hospital; Central Hospital of Minhang District, Shanghai; Putuo District People's Hospital of Shanghai; Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Tianjin Medical University Cancer Hospital; First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Kunming Medical College; Yinzhou Hospital Affiliated to Medical School of Ningbo University; Shaoxing Second Hospital; Shaoxing People's Hospital; First Affiliated Hospital of Wenzhou Medical University; Sir Run Run Shaw Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang University; Zhejiang Cancer Hospital; Huzhou Central Hospital; Ningbo No. 1 Hospital; People's Hospital of Hunan Province; Hainan Provincial People's Hospital; Taizhou Municipal Hospital; Xinghua City People's Hospital; Tongliao City Hospital; Jiangxi Provincial Cancer Hospital; Shandong Provincial Hospital; Qilu Hospital of Shandong University; The Affiliated Hospital of Qingdao University; Xijing Hospital
Recruiting
Feeds
50472 items (50472 unread) in 74 feeds
Acinar Cell Carcinoma
(316 unread)
Acinic Cell Carcinoma
(234 unread)
Adenoid Cystic Carcinoma
(994 unread)
Adrenal Gland Cancer
(4521 unread)
Ampulla Of Vater
(1119 unread)
Anal Cancer
(4932 unread)
Angiosarcoma
(1529 unread)
Appendix Cancer
(693 unread)
Bile Duct Cancer
(6363 unread)
Brain and CNS
(6633 unread)
Carcinoid
(2148 unread)
Endocrine/Neuroendocrine
(5393 unread)
Gall Bladder Cancer
(2319 unread)
Hemangioendothelioma
(701 unread)
Hepatoblastoma
(730 unread)
Pancreas
(701 unread)
Phyllodes
(396 unread)
PMP and Mucinous Tumors
(453 unread)
Rhabdomyosarcoma
(1967 unread)
Sarcoma
(8330 unread)
Trials - Gall Bladder Cancer (45 unread)
-
Chinese Research Group of Gallbladder Cancer
Posted: October 28th, 2019, 2:00pm GMT
-
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
Posted: October 21st, 2019, 2:00pm GMT
Condition: Primary Sclerosing Cholangitis
Interventions: Drug: Simvastatin 40mg; Drug: Placebo oral tablet
Sponsor: Annika Bergquist
Not yet recruiting -
Quebec Pancreas Cancer Study
Posted: September 26th, 2019, 2:00pm GMT
Conditions: Pancreas Cancer; Pancreatic Cancer; Pancreas Neoplasm; Pancreas Cyst; Pancreatic Precancerous Condition; Familial Pancreatic Cancer; Hereditary Cancer; Bile Duct Cancer; Ampullary Cancer; Duodenal Cancer; Gallbladder Cancer
Intervention:
Sponsor: George Zogopoulos
Recruiting -
BLESSED: Expanded Access for DeltaRex-G for Advanced Solid Tumors, Lymphoma and Multiple Myeloma
Posted: September 16th, 2019, 2:00pm GMT
Conditions: Pancreatic Adenocarcinoma; Osteosarcoma; MPNST (Malignant Peripheral Nerve Sheath Tumor); Chondrosarcoma; Soft Tissue Sarcoma; Glioblastoma; Carcinoma of Breast; Lymphoma; Multiple Myeloma; Gall Bladder Cancer; Chordoma; All Solid Tumors
Intervention: Drug: DeltaRex-G
Sponsor: Aveni Foundation
Available -
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Posted: August 28th, 2019, 2:00pm GMT
Conditions: Advanced Bile Duct Carcinoma; Advanced Gallbladder Carcinoma; Refractory Bile Duct Carcinoma; Refractory Gallbladder Carcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8
Interventions: Drug: Irinotecan; Drug: Irinotecan Hydrochloride; Drug: Trifluridine and Tipiracil Hydrochloride
Sponsors: Mayo Clinic; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting -
Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Posted: August 26th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; Advanced Gallbladder Carcinoma; Advanced Malignant Solid Neoplasm; Metastatic Cholangiocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Gallbladder Carcinoma; Refractory Malignant Solid Neoplasm; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Hilar Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Hilar Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIC Hilar Cholangiocarcinoma AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVA Hilar Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Stage IVB Hilar Cholangiocarcinoma AJCC v8
Interventions: Drug: Avelumab; Radiation: Hypofractionated Radiation Therapy; Drug: Nedisertib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Gemcitabine Plus Cisplatin With or Without M7824 in Participants With 1L Biliary Tract Cancer (BTC)
Posted: August 23rd, 2019, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: M7824; Drug: Placebo; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Posted: August 16th, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Combination Product: Combination of Lonsurf® and Campto®
Sponsors: RWTH Aachen University; Servier
Not yet recruiting -
To Study the Role of Liquid Based Cytology (LBC) for Diagnosis and Characterization of Biliopancreatic Tumor s Compared With Standard Cytology and On-site Evaluation.
Posted: July 17th, 2019, 2:00pm GMT
Condition: Pancreatobiliary-Type Carcinoma
Interventions: Diagnostic Test: Liquid based cytology; Diagnostic Test: Conventional cytology
Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Posted: July 1st, 2019, 2:00pm GMT
Condition: Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Posted: June 27th, 2019, 2:00pm GMT
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
Posted: June 13th, 2019, 2:00pm GMT
Conditions: Tumor, Solid; Gall Bladder Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Pancreatic Cancer; Clear Cell Renal Cell Carcinoma
Intervention: Drug: Andes-1537 for Injection
Sponsor: Andes Biotechnologies
Recruiting -
Bile Composition in Healthy and Gallstones Patients
Posted: June 10th, 2019, 2:00pm GMT
Conditions: Cholelithiasis; Gall Stone; Gall Bladder Disease
Interventions: Diagnostic Test: Bile test; Diagnostic Test: Blood test; Diagnostic Test: Gall stone study; Diagnostic Test: Microbiological bile test
Sponsor: Hospital Son Espases
Not yet recruiting -
Fluorescence Imaging in Hepatobiliary Surgery
Posted: May 13th, 2019, 2:00pm GMT
Condition: Hepatobiliary Surgery
Interventions: Drug: Indocyanine Green; Device: Cancer goggle system
Sponsor: Washington University School of Medicine
Not yet recruiting -
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Posted: May 6th, 2019, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Not yet recruiting -
Analysis of the Impact of Cholecystectomy on Gut Microbiome in Adults
Posted: February 11th, 2019, 3:00pm GMT
Condition: Laparoscopic Cholecystectomy
Intervention: Procedure: Laparoscopic cholecystectomy
Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting -
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Posted: February 7th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Posted: January 11th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Recruiting -
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
Posted: December 7th, 2018, 3:00pm GMT
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting -
Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer
Posted: December 4th, 2018, 3:00pm GMT
Conditions: Gallbladder Diseases; Healthy
Intervention: Other: Benigh gallbladder diseases
Sponsor: Tongji Hospital
Not yet recruiting -
Primary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.
Posted: November 5th, 2018, 3:00pm GMT
Condition: Acute Cholecystitis
Interventions: Procedure: EUS-guided gallbladder drainage; Procedure: Non EUS-guided gallbladder drainage
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Recruiting -
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Posted: October 24th, 2018, 2:00pm GMT
Conditions: Pancreatic Cancer; Resectable Pancreatic Cancer
Interventions: Drug: Pimonidazole; Procedure: Surgical Resection
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Varian Medical Systems
Not yet recruiting -
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Stage I Gallbladder Cancer AJCC v8; Stage II Gallbladder Cancer AJCC v8; Stage IIA Gallbladder Cancer AJCC v8; Stage IIB Gallbladder Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8
Interventions: Drug: Capecitabine; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Emory University
Recruiting -
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
Posted: March 22nd, 2018, 2:00pm GMT
Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma Non-resectable; Gallbladder Carcinoma Non-Resectable
Interventions: Biological: Durvalumab; Drug: Gemcitabine; Drug: Cisplatin; Biological: Tremelimumab
Sponsors: AIO-Studien-gGmbH; AstraZeneca
Recruiting -
Surgical Apgar Score After Whipple Procedure in Pancreatic Cancer Patients
Posted: March 20th, 2018, 2:00pm GMT
Condition: Postoperative Complications
Intervention: Other: Observe postoperative complications
Sponsor: Tata Memorial Hospital
Recruiting -
Integrative Medicine for Chemotherapy-Induced Peripheral Neuropathy
Posted: September 25th, 2017, 2:00pm GMT
Condition: Chemotherapy-induced Peripheral Neuropathy
Interventions: Other: Acupuncture; Other: Multi-modality (Acupuncture "plus")
Sponsors: The Chaim Sheba Medical Center; Bnai Zion Medical Center; Lin Medical Center, Haifa; Carmel Medical Center
Recruiting -
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Posted: August 22nd, 2017, 2:00pm GMT
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Posted: July 6th, 2017, 2:00pm GMT
Conditions: Peritoneum Cancer; Peritoneum Neoplasm; Pleural Cancer; Pleural Effusion; Pleural Mesothelioma; Ovarian Cancer; Gastric Cancer; Appendix Cancer; Pseudomyxoma Peritonei; Colorectal Cancer; Pancreas Cancer; Gallbladder Cancer; Ascites; CUP; Chemotherapeutic Toxicity
Intervention: Combination Product: PIPAC
Sponsors: Sabine Rhode; Ruhr University of Bochum
Recruiting -
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Posted: April 28th, 2017, 2:00pm GMT
Conditions: Radiation Therapy; Cancer; Cancer of Anus; Cancer of Bladder; Cancer of Cervix; Cancer of Colon; Cancer of Rectum; Cancer of Esophagus; Cancer of Gallbladder; Cancer of Liver; Cancer of Ovary; Cancer of Pancreas; Cancer of Prostate; Cancer of Kidney and Renal Pelvis; Cancer of Stomach; Cancer of Testis; Cancer of Uterus; Cancer of Uterus and Cervix; Cancer of Kidney
Intervention:
Sponsors: DxTerity Diagnostics; National Cancer Institute (NCI)
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Posted: February 6th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire)
Recruiting -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Posted: October 5th, 2016, 2:00pm GMT
Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting -
Hepatic Resection for Metastatic Pancreatic Cancer
Posted: September 8th, 2016, 2:00pm GMT
Conditions: Pancreatic Neoplasms; Neoplasm Metastasis; Liver Metastases
Intervention: Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy
Sponsor: Duke University
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer
Posted: June 22nd, 2016, 2:00pm GMT
Condition: Biliary Tract Neoplasms
Intervention: Procedure: surgery or biopsy
Sponsors: RenJi Hospital; Huadong Hospital; Shanghai Changzheng Hospital; Yangpu District Central Hospital Affiliated to Tongji University
Recruiting -
The Role of Different Imaging Methods in the Diagnosis of Gallbladder Polyps
Posted: May 4th, 2016, 2:00pm GMT
Condition: Polyp of Gallbladder
Interventions: Device: Abdominal high resolution CT; Device: Contrast-enhanced ultrasonography (CEUS); Procedure: Cholecystectomy
Sponsor: RenJi Hospital
Recruiting -
A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
Posted: January 20th, 2016, 3:00pm GMT
Conditions: Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; HCC; AOV Cancer
Interventions: Procedure: side by side; Procedure: stent in stent
Sponsor: Yonsei University
Recruiting -
Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Posted: January 5th, 2016, 3:00pm GMT
Condition: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Interventions: Device: Radiofrequency ablation with stenting; Device: stenting
Sponsor: Yonsei University
Recruiting -
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Posted: December 16th, 2015, 3:00pm GMT
Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting -
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Posted: August 11th, 2015, 2:00pm GMT
Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms
Posted: April 30th, 2015, 2:00pm GMT
Condition: Gallbladder Neoplasms
Interventions: Procedure: Irreversible electroporation (IRE); Device: NanoKnife
Sponsor: Fuda Cancer Hospital, Guangzhou
Recruiting -
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Posted: January 29th, 2015, 3:00pm GMT
Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Uterine Cancer; Mesotheliomas; Gastrointestinal Cancers; Cervical Cancer
Interventions: Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min; Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0; Device: HIPEC: CDDP 75 mg/m2 @T0; Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Sponsor: Bay Area Gynecology Oncology
Recruiting -
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
Posted: January 7th, 2015, 3:00pm GMT
Condition: Hepatic Carcinoma
Intervention: Device: NanoKnife
Sponsor: Fuda Cancer Hospital, Guangzhou
Recruiting -
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
Posted: June 23rd, 2014, 2:00pm GMT
Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Deutsche Krebshilfe e.V., Bonn (Germany); Cancer Research UK; Australasian Gastro-Intestinal Trials Group; Dutch Hepato Cellular & Cholangio Carcinoma Group (DHCG)
Recruiting -
Integrated Cancer Repository for Cancer Research
Posted: December 16th, 2013, 3:00pm GMT
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; GIST; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; CNS Tumor; CNS Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control
Intervention:
Sponsor: University of Nebraska
Recruiting